Speakers 2025

Speakers 2021 2022 2023 2024 2025

Marina DESCHAMPS

RIGHT INSTITUTE


CAR-T CELLS (KURSAAL CONF ROOM)

From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor interactions and in anti-tumor immunotherapy approaches. Based on the monitoring of the suicide gene therapy clinical trial to control Graft vs Host Disease (GvHD) has allowed me to acquire a great experience on T-cells gene therapy. Building on this experience, as the scientific responsible, I have contributed to develop a new suicide gene clinical trial based on iCasp9/Rimiducid®. This clinical trial “Side by CIDe” (ClinicalTrials.gov Identifier: NCT02849886) is approved by the French regulatory agency (ANSM) in the context of the new ATMP European regulations and is open for recruitment. The expertise acquired from gene transfer and vectorology for more than 19 years, has been naturally transposed to develop anti-tumor immunotherapy approaches based on LT reprogramming with Chimeric Antigen Receptor (CAR) or transgenic TCR (TCRtg). My involvement in the different study of gene modified T cells, and more recently in CART cells, and my scientific and technical background in the field of cellular immunotherapies based in competences in molecular biology / vectorology, viral supernatant production, cell and gene engineering in closed system GMP compliant (Good Manufacturing Process), integration of the validation processes for regulatory reviews by ANSM for clinical trial approval and biomonitoring of patients, have enabled me to develop strong translational research expertise applied in hematology and solid tumor.   The expertise acquired within the EFS led me to co-found the startup CanCell Therapeutics where I am managing director and head of translational research and development. Our aim is to develop, particularly in oncology, new Advanced Therapy Medicinal Products (ATMP) in the field of immunotherapy up to their commercialization.

Find also


Sylvain PERRUCHE

MED’INN’PHARMA

Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...

En savoir +

Sylvie MERCIER

RD Biotech

After studying biology at the University of Sciences in Besançon, Sylvie defended her thesis based on cytogenetic and molecular prenatal diagnostic tools in Pr. Bresson's cytogenetics laboratories in Besançon. Then she went to Montreal, Quebec, as a laboratory coordinator at...

En savoir +

MAGALON Jérémy

Département de Bioingéniérie Pharmaceutique, Faculté de Pharmacie

European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...

En savoir +

Christophe FERRAND

RIGHT INSTITUTE

Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...

En savoir +

Agnès FOURCOT

After a master's degree in genetics and a Ph.D. on the role of Gas6 protein and precursor cells in steatohepatitis and hepatic fibrosis, Agnès advised companies in many sectors, particularly in industry, as a consultant in innovation financing. She was...

En savoir +

John DE VOS

CHU Montpellier, INSERM U1183

John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...

En savoir +

Olivier HUMBEY

IQVIA

Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...

En savoir +